hydron;N-methyl-2-pyridin-2-ylethanamine;dichloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: hydron;N-methyl-2-pyridin-2-ylethanamine;dichloride
• 化学式: C8H14Cl2N2
• mdl: MFCD00012813
• 分子量: 209.11
• InChiKey: XVDFMHARQUBJRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.63
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  24.9
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (5-氯-1H-苯并咪唑-2-基)(4-甲基-1-哌嗪基)甲酮 、 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methyl piperazine maleate 、 二甲基亚砜 生成 hydron;N-methyl-2-pyridin-2-ylethanamine;dichloride 、 thioperamide maleate
  参考文献：
  名称：

  Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders

  摘要：

  该发明涉及组胺H4受体拮抗剂或组胺H4受体基因表达抑制剂，用于治疗和/或预防前庭障碍。

  公开号：

  US20120039913A1

文献信息

• Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and "unnatural" UDP- and TDP-nucleotide sugars
  申请人：——

  公开号：US20030055235A1

  公开（公告）日：2003-03-20

  The present invention provides mutant nucleotidylyl-transferases, such as E p , having altered substrate specificity; methods for their production; and methods of producing nucleotide sugars, which utilize these nucleotidylyl-transferases. The present invention also provides methods of synthesizing desired nucleotide sugars using natural and/or modified Ep or other nucleotidyltransferases; and nucleotide sugars sythesized by the present methods. The present invention further provides new glycosyl phosphates, and methods for making them.

  本发明提供了一种突变型核苷酸转移酶，如E p ，具有改变的底物特异性；其生产方法；以及利用这些核苷酸转移酶生产核苷酸糖的方法。本发明还提供了使用天然和/或修饰的Ep或其他核苷酸转移酶合成所需的核苷酸糖的方法；以及通过本发明方法合成的核苷酸糖。本发明进一步提供了新的糖基磷酸酯，及其制造方法。
• MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS
  申请人：Genomatica, Inc.

  公开号：US20150148513A1

  公开（公告）日：2015-05-28

  The invention provides non-naturally occurring microbial organisms having a 4-hydroxybutyrate, 1,4-butanediol, or other product pathway and being capable of producing 4-hydroxybutyrate, 1,4-butanediol, or other product, wherein the microbial organism comprises one or more genetic modifications. The invention additionally provides methods of producing 4-hydroxybutyrate, 1,4-butanediol, or other product or related products using the microbial organisms.

  该发明提供了具有4-羟基丁酸、1,4-丁二醇或其他产物途径并能够产生4-羟基丁酸、1,4-丁二醇或其他产物的非自然微生物生物体，其中该微生物生物体包括一个或多个基因修饰。该发明还提供了利用这些微生物生物体生产4-羟基丁酸、1,4-丁二醇或其他产物或相关产品的方法。
• [EN] QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES<br/>[FR] QUINOLÉINES ET LEUR UTILISATION POUR TRAITER LES MALADIES DUES AU STRESS DU RÉTICULUM ENDOPLASMIQUE
  申请人：CELLADON CORP

  公开号：WO2016032569A1

  公开（公告）日：2016-03-03

  Provided herein are quinolines, e.g., a compound of Formula (I) or (IB), pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caused disease. Also provided herein are methods of their use for reducing endoplasmic reticulum stress and modulating the activity of a sarcoplasmic/endoplasmic reticulum Ca2+ ATPase.

  本文提供了喹啉类化合物，例如，化合物的化学式为（I）或（IB），以及其药物组合物，并用于治疗、预防或改善内质网应激引起的一种或多种疾病症状的方法。本文还提供了用于减少内质网应激并调节肌浆/内质网Ca2+ ATP酶活性的方法。
• [EN] ANTIMALARIAL AGENTS<br/>[FR] AGENTS ANTIPALUDIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2021101836A1

  公开（公告）日：2021-05-27

  The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

  本发明提供了治疗疟疾的方法，包括向需要的受试者施用化合物I式或其药用可接受的盐，其中变量如本文所定义。该发明还提供了化合物I式的用途，如本文所定义，用于可能抑制血浆蛋白酶X、血浆蛋白酶IX或血浆蛋白酶X和IX活性，用于治疗疟原虫感染和治疗疟疾。还提供了治疗方法，进一步包括施用一种或多种额外的抗疟疾化合物。
• Malonic acid based matrix metalloproteinase inhibitors
  申请人：ROCHE DIAGNOSTICS GMBH

  公开号：US20020049185A1

  公开（公告）日：2002-04-25

  There is described the use of a compound represented by general formulae (I), (II) or (III), for the inhibition of matrix metalloproteinases (MMP), wherein X 1 is oxygen or sulfur, R 1 is OH, SH, CH 2 OH, CH 2 SH or NHOH, R 2 is a residue of 2 to 10 hydrocarbon backbone atoms, which binds to the amino acid 161 of HNC, said residue being saturated or unsaturated, linear or branched, and contains preferably homocyclic or heterocyclic structures, X 2 is oxygen or sulfur and binds as hydrogen acceptor on amino acid 160 of HNC, Y is a residue which binds to the S1′ pocket of HNC and consists of at least 4 backbone atoms Z 1 -Z 2 -Z 3 -Z 4 -R 3 , and R 3 is n-propyl, isopropyl, isobutyl or a residue with at least 4 backbone atoms, which is not larger than a tricyclic ring system. These compounds bind to MMPs in a manner different from the mode of binding of the inhibitors of the state of the art.

  描述了一种化合物的用途，其表示为通用式(I)、(II)或(III)，用于抑制基质金属蛋白酶(MMP)，其中X1是氧或硫，R1是OH、SH、CH2OH、CH2SH或NHOH，R2是由2到10个碳骨架原子组成的残基，该残基与HNC的氨基酸161结合，该残基饱和或不饱和，直链或支链，并且最好包含同环或异环结构，X2是氧或硫，并且作为氢受体结合到HNC的氨基酸160上，Y是一个残基，结合到HNC的S1'口袋，并由至少4个骨架原子Z1-Z2-Z3-Z4-R3组成，R3是正丙基、异丙基、异丁基或具有至少4个骨架原子的残基，不大于三环环系统。这些化合物以一种与现有技术的抑制剂的结合方式不同的方式结合到MMP。

表征谱图